文献速递自身炎症与 IgG4 相关病

卡那单抗治疗冷吡啉相关周期性综合征的长期安全性与有效性:β-Confident登记研究

Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry.
PubMed 文献 · RMD Open · 2021-01-01

β-Confident登记研究前瞻性纳入285例患者(其中CAPS 243例),评估卡那单抗长期治疗的安全性和有效性,随访长达6年。48个月时47.2%的CAPS患者PGA评估无疾病活动,52.8%为轻中度活动;FCAS不良事件发生率最低(73.1/100患者年),CAPS患者严重不良事件发生率为14.0/100患者年,报告1例死亡。结论认为卡那单抗疗效可持续长达6年且安全性良好。

要点

  • 卡那单抗在CAPS患者中疗效可持续长达6年,48个月时47.2%无疾病活动。
  • FCAS不良事件发生率(73.1/100患者年)低于MWS(105.0)和NOMID(104.6)。
  • CAPS患者严重不良事件发生率为14.0/100患者年,报告1例死亡。

核心结论

  • 卡那单抗在CAPS患者中的治疗反应可持续长达6年,长期治疗显示良好的安全性特征。

研究设计与样本

  • β-Confident登记研究为前瞻性队列,2009年12月至2015年12月纳入接受卡那单抗常规治疗并前瞻性随访长达6年的CAPS及非CAPS患者。
  • 登记方案未规定特定访视或操作,但要求记录所有观察到的不良事件和严重不良事件。
  • 中位年龄26.6岁;有效性采用医师整体评估(PGA)评价。

主要发现

  • 基于PGA,123例CAPS患者中58例(47.2%)在48个月时无疾病活动,65例(52.8%)为轻中度疾病活动。
  • CAPS各表型中,FCAS的不良事件发生率为73.1/100患者年(95%CI 60.3至87.8),低于MWS的105.0/100患者年(95%CI 97.2至113.2)和NOMID的104.6/100患者年(95%CI 86.6至125.2)。
  • 报告1例死亡(MWS患者发生转移性直肠腺癌)。

关键数值与推荐

  • 有效性评价采用医师整体评估(PGA),48个月时CAPS患者无疾病活动比例为47.2%(58/123)。
  • FCAS不良事件发生率73.1/100患者年(95%CI 60.3至87.8),MWS为105.0/100患者年(95%CI 97.2至113.2),NOMID为104.6/100患者年(95%CI 86.6至125.2)。
  • CAPS患者严重不良事件发生率14.0/100患者年(95%CI 11.6至16.6)。

临床怎么用

  • 在真实世界实践中,卡那单抗长期治疗CAPS可维持疾病活动控制达6年。
  • 长期治疗期间需持续监测不良事件和严重不良事件,尤其MWS和NOMID患者不良事件发生率较高。

局限性

  • 登记方案未规定特定访视或操作,可能影响数据采集的标准化程度。
  • 有效性分析仅基于123例CAPS患者的PGA数据,部分患者缺乏48个月评估。
  • 随访期内报告1例死亡,但登记研究设计无法确立因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report the long-term safety and effectiveness of canakinumab, a fully human anti-interleukin 1β monoclonal antibody, in patients with cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS) and neonatal-onset multisystem inflammatory disease (NOMID), in a real-world setting. METHODS: From December 2009 to December 2015, the β-Confident Registry prospectively enrolled patients with CAPS and non-CAPS conditions who received canakinumab per routine care and were prospectively followed for up to 6 years. The registry protocol did not mandate specific visits or procedures; however, all observed adverse events (AEs) and serious adverse events (SAEs) had to be recorded. Canakinumab effectiveness was evaluated by Physician's Global Assessment (PGA). RESULTS: Of 288 patients enrolled, 3 were excluded due to missing informed consent. Among the remaining 285 patients, 243 (85.3%) were patients with CAPS and 42 (14.7%) had atypical CAPS (6.3%) or other conditions (8.4%). The median age was 26.6 years. Based on PGA, 58 of 123 (47.2%) patients with CAPS had no disease activity at 48 months, and 65 of 123 (52.8%) experienced mild/moderate disease activity at 48 months. Among CAPS phenotypes, AE incidence rates per 100 patient-years were lowest for FCAS (73.1; 95% CI 60.3 to 87.8) compared with those with MWS (105.0; 95% CI 97.2 to 113.2) or NOMID (104.6; 95% CI 86.6 to 125.2). One hundred twenty-eight SAEs were reported in 68 patients with CAPS (incidence rate/100 patient-years, 14.0; 95% CI 11.6 to 16.6). One death (metastatic rectal adenocarcinoma in a patient with MWS) was reported. CONCLUSIONS: The response to canakinumab was sustained for up to 6 years. Canakinumab demonstrated a favourable safety profile over long-term treatment in patients with CAPS. TRIAL REGISTRATION NUMBER: NCT01213641.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Walker UA, Tilson HH, Hawkins PN, et al. Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry. RMD Open. 2021. PMID: 34001647. doi:10.1136/rmdopen-2021-001663

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。